NXP2-positive dermatomyositis complicated with refractory skin edema: Successful treatment with tocilizumab

Dermatol Ther. 2021 Jan;34(1):e14712. doi: 10.1111/dth.14712. Epub 2021 Jan 4.

Authors

Zihan Lu¹, Yanan Chen¹, Jing Xue², Lei Liu²

Affiliations

¹ Department of Dermatology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
² Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.

PMID: 33368804
DOI: 10.1111/dth.14712

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Autoantibodies
Dermatomyositis* / complications
Dermatomyositis* / diagnosis
Dermatomyositis* / drug therapy
Edema / diagnosis
Edema / drug therapy
Edema / etiology
Humans

Substances

Antibodies, Monoclonal, Humanized
Autoantibodies
tocilizumab